Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
AbbVie Inc.
IndexS&P 500 P/E29.31 EPS (ttm)2.31 Insider Own0.08% Shs Outstand1.59B Perf Week3.74%
Market Cap107.89B Forward P/E15.91 EPS next Y4.26 Insider Trans0.08% Shs Float1.57B Perf Month3.37%
Income3.71B PEG2.33 EPS next Q0.86 Inst Own89.50% Short Float1.38% Perf Quarter16.18%
Sales19.62B P/S5.50 EPS this Y-23.10% Inst Trans10.84% Short Ratio1.76 Perf Half Y27.88%
Book/sh2.91 P/B23.27 EPS next Y28.92% ROA12.90% Target Price69.57 Perf Year32.82%
Cash/sh4.85 P/C13.96 EPS next 5Y12.58% ROE77.90% 52W Range44.82 - 70.76 Perf YTD32.35%
Dividend1.96 P/FCF50.56 EPS past 5Y0.00% ROI23.20% 52W High-4.85% Beta-
Dividend %2.89% Quick Ratio2.50 Sales past 5Y- Gross Margin76.90% 52W Low50.21% ATR1.42
Employees25000 Current Ratio2.60 Sales Q/Q7.80% Oper. Margin29.00% RSI (14)55.34 Volatility2.45% 1.96%
OptionableYes Debt/Eq3.18 EPS Q/Q-48.30% Profit Margin18.90% Rel Volume1.37 Prev Close67.71
ShortableYes LT Debt/Eq3.11 EarningsOct 31 BMO Payout70.40% Avg Volume12.32M Price67.33
Recom2.10 SMA20-0.90% SMA506.22% SMA20020.70% Volume5,961,056 Change-0.56%
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Dec-22-14 11:25AM  The Winner of the AbbVie-Gilead Hep-C Battle? Express Scripts at
11:25AM  Express Scripts Picks AbbVie HCV Drugs Over Gilead at Investor's Business Daily
11:20AM  AbbVie's Exclusive Hepatitis C Deal With Express Scripts: What Wall Street's Saying at TheStreet
11:15AM  The Hepatitis C Price Wars Begin: What the Express Scripts Move Means at The Wall Street Journal
11:11AM  Gilead Sciences: How Much Does AbbVie's Express Scripts Deal Hurt? at
09:55AM  [video] Mon., Dec. 22: Watch Staples After Data Breach at MarketWatch
09:46AM  Gilead Sciences Plummets Amid AbbVie Deal With Express Scripts Benzinga
09:28AM  AbbVie gets exclusive hepatitis C billing at CNBC
09:17AM  AbbVie gets boost from Express Scripts; American Apparel confirms a suitor; Sony may release 'The Interview' Hot Stock Minute
09:16AM  Express Scripts selects AbbVie over Gilead CNBC
09:10AM  Stock Futures Point Higher; AbbVie Surges, Gilead Dives at Investor's Business Daily
08:59AM  US STOCKS-Wall St set to open up after three-day run; data on tap Reuters
08:52AM  U.S. stocks: Futures point to higher open; existing-home sales next at MarketWatch
08:52AM  Cramer's view of AbbVie-Express Scripts deal CNBC
08:50AM  Express Scripts picks AbbVie's hep C drug over Gilead's CNBC
08:19AM  Stock market may wish investors a wary Christmas at MarketWatch
08:18AM  US STOCKS-Futures advance after three-day rally; data on tap Reuters
07:45AM  US STOCKS-Futures climb after three-day run Reuters
07:45AM  Express Scripts shuts out Gilead in deal with AbbVie for hepatitis drug at
07:41AM  Wall Street set to extend last week's rally; Express Scripts picks AbbVie drug; Sony attorney says 'The Interview' will get out Hot Stock Minute
07:00AM  Express Scripts and AbbVie Make Hepatitis C Cure Available to Millions of Patients in Need PR Newswire
06:35AM  Express Scripts gets deal for AbbVie's hepatitis C drug CNBC
06:14AM  Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market at TheStreet
12:01AM  Express Scripts to cover AbbVie hepatitis C drug, drops Gilead treatment Reuters
12:00AM  2015 Guide for Deal Watchers: Pfizer to MegaBrew Bloomberg
Dec-19-14 08:02PM  U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks Reuters
06:45PM  AbbVie says newly approved hepatitis C treatment costs $83,319 Reuters
06:27PM  [$$] FDA Backs AbbVie's Hepatitis Treatment at The Wall Street Journal
05:23PM  AbbVie's Hepatitis-C Treatment Approved, Bad news for Gilead? at
04:16PM  Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next at TheStreet
03:33PM  FDA approves AbbVies hepatitis treatment at MarketWatch
03:02PM  U.S. FDA approves AbbVie all-oral hepatitis C treatment Reuters
Dec-18-14 02:36PM  An overview of Maverick Capitals 3Q14 13F Market Realist
01:11PM  AbbVie: Here's How It Could Differentiate Itself From Gilead at
12:15AM  AbbVie Pins Hopes on Hepatitis C Treatment at The Wall Street Journal
Dec-17-14 07:52PM  AbbVie Pins Hopes on Hepatitis C Treatment at The Wall Street Journal
12:06PM  Shire considering bid for NPS Pharmaceuticals - Bloomberg Reuters
11:01AM  Shire Said to Weigh Offer for NPS as It Revisits Deals at Bloomberg
Dec-16-14 10:21AM  Viekirax/Exviera vs. Harvoni: Clash of the Hep C Drugs 2015 Yahoo Finance Blogs
Dec-12-14 08:50AM  Abbvie (ABBV) Upgraded From Hold to Buy at TheStreet
Dec-11-14 10:21AM  Will AbbVie Undercut Gilead on Hepatitis C? at
08:56AM  Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers TheStreet
08:01AM  Gilead Is Growing Fast And Its Stock Is Cheap at
Dec-10-14 07:37PM  Walgreens CEO announces plans to step down at USA TODAY
04:20PM  Roche (RHHBY) Presents Positive Data on Haemophilia Drug Zacks
11:59AM  AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH (Revised) Zacks
Dec-09-14 01:45PM  Gilead Sciences: Still Waiting on AbbVie at
Dec-08-14 01:50PM  AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH Zacks
Dec-07-14 08:15PM  AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting PR Newswire
Dec-06-14 06:00AM  Jim Cramer's Top Stock Picks: LE ABBV ULTA IDXX at TheStreet
Dec-05-14 06:22PM  Cramer's story of a big pharma comeback at CNBC
04:49PM  Sanofi Buys Merck's Manufacturing Facility in Puerto Rico Zacks
02:55PM  Will MedTech Gain from Republican Promises? Zacks
Dec-03-14 01:21PM  Bulls can't get enough of Abbott Labs optionMONSTER
07:14AM  Abbott Labs attracts bullish trades optionMONSTER
05:45AM  Bullish Options Buyers Are Turning to Abbott Laboratories at TheStreet
Dec-02-14 11:29AM  Billionaires are dumping these 3 stocks at
08:02AM  Meet 5 Top Drug Stocks That Are Bolting Past Market at Investor's Business Daily
12:01AM  AbbVie, Intel, Sony, BCE : Intellectual Property at Bloomberg
Dec-01-14 05:01PM  Large Cap All-Time Highs List... Yahoo Finance Blogs
Nov-30-14 07:01PM  'Milestone' in fight against Aids as treatment outpaces infections at Financial Times
07:01PM  AbbVie adds children's AIDS drugs to shared patent pool Reuters
Nov-28-14 02:18PM  5 Stock-Moving Medtech Events This December at Investor's Business Daily
08:34AM  The Zacks Analyst Blog Highlights: BioMarin, Prosensa, Five Prime Therapeutics, AbbVie, Amgen, Biogen and Vertex Zacks
Nov-26-14 04:23PM  Paulson & Co. adds a significant position in AbbVie Market Realist
12:20PM  FDA Seeks More Data on Bristol-Myers Hepatitis C Therapy at The Wall Street Journal
09:54AM  Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval Zacks
Nov-24-14 06:00PM  AbbVie's HCV Cocktail Treatment Closer to EU Approval Zacks
05:54PM  Inversions Become Political Hazard as Stryker Weighs Deal Bloomberg
04:48PM  Most Sectors Represent in Today's Lg Cap All-Time Highs... Yahoo Finance Blogs
10:54AM  Hedge funds playing buy-and-hold, and losing at CNBC
Nov-21-14 10:02PM  John Paulson's Top 5 New Holdings for Q3 Gurufocus
04:00PM  Amgen and AbbVie Strengthen Manufacturing Facilities in Asia Zacks
08:19AM  Drug Name or Pokemon? It's Getting Harder to Tell the Difference Yahoo Finance Blogs
08:00AM  CHMP Grants Positive Opinions of AbbVie's VIEKIRAX (ombitasvir/paritaprevir/ritonavir) + EXVIERA (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe PR Newswire
07:20AM  Europe gives green light to AbbVie hepatitis C medicine, others Reuters
Nov-20-14 09:00PM  AbbVie Acquires Manufacturing Facility in Singapore; Further Expands Capabilities in Asia PR Newswire
11:50AM  Billionaire ETF Index Adds Facebook, Dumps Netflix, Others ETF Trends
Nov-19-14 03:20PM  AstraZeneca Targets More than $45B in Revenues in 2023 Zacks
02:50PM  Pharma Industry Outlook: M&A, Licensing Abound Zacks
12:25PM  'More Biotechy?' Shire to Move US HQ and 500 Jobs to Greater Boston at The Wall Street Journal
Nov-18-14 04:41PM  Health Care dominates the Lg Cap All-Time Highs today... Yahoo Finance Blogs
03:44PM  Novartis Presents Data on Heart Failure Candidate LCZ696 Zacks
Nov-17-14 06:27PM  Will IPOs WhiteWave, Enanta Surpass Buy Points? at Investor's Business Daily
06:27PM  Five Ethical Drugmakers Keep Leadership Positions at Investor's Business Daily
05:34PM  Ownership Roundup: Buffett and the Hedge Funds at 3Q at
09:00AM  AbbVie to Present Data on Investigational Oncology Compounds at the 56th American Society of Hematology Annual Meeting PR Newswire
07:00AM  AbbVie to Present at Jefferies 2014 Global Healthcare Conference PR Newswire
Nov-14-14 06:46PM  Paulson takes stake in Abbvie, adds to Shire holdings at MarketWatch
04:48PM  AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology PR Newswire
01:04PM  ABBVIE INC. Financials EDGAR Online Financials
12:22PM  Coverage initiated on AbbVie by Deutsche Bank
Nov-13-14 03:48PM  Can Gilead Recover from 3Q? at
09:15AM  4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic at 24/7 Wall St.
09:00AM  AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA┬« (adalimumab) PR Newswire
07:36AM  The Zacks Analyst Blog Highlights: Dendreon, Amgen, Regeneron, AbbVie and Gilead Zacks
Nov-12-14 12:51PM  European Ombudsman Questions EMA Redactions of AbbVie Trial Data at The Wall Street Journal
Nov-11-14 12:25PM  Will Time Warner-Comcast Deal Survive Net Neutrality? at
10:23AM  AbbVie, Enanta drug shows potential in hep C genotype 4 patients Reuters
09:00AM  AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting┬« 2014 PR Newswire
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. It has a strategic collaboration with Infinity Pharmaceuticals, Inc.; and a research and development collaboration with California Life Sciences LLC. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HURWICH THOMAS A.VP, ControllerNov 24Sale67.811,500101,71763,211Nov 26 05:00 PM
HURWICH THOMAS A.VP, ControllerNov 06Option Exercise24.0710,000240,73171,448Nov 07 05:57 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 04Sale51.204,799245,706395,403Mar 04 05:13 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 03Sale50.034,143207,284273,585Mar 04 05:18 PM
SALEKI-GERHARDT AZITASVP, OperationsMar 03Sale50.252,443122,76085,828Mar 04 05:17 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 03Sale50.223,948198,259180,068Mar 04 05:12 PM
ALBAN CARLOSEVP, Commercial OperationsMar 03Sale50.092,882144,356205,138Mar 04 05:10 PM
HURWICH THOMAS A.VP, ControllerFeb 18Option Exercise44.939,138410,57061,016Feb 19 05:33 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCFeb 18Option Exercise43.218,928385,779256,224Feb 19 05:35 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 18Sale51.2346523,82283,913Feb 19 05:35 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 10Option Exercise45.061,46666,05865,856Feb 12 04:49 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Sale47.8468732,86664,390Feb 07 05:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 05Sale47.781,46069,76385,470Feb 07 05:08 PM